These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25576353)

  • 1. Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study.
    Wozniak AJ; Kosty MP; Jahanzeb M; Brahmer JR; Spigel DR; Leon L; Fish S; Flick ED; Hazard SJ; Lynch TJ
    Clin Oncol (R Coll Radiol); 2015 Apr; 27(4):187-96. PubMed ID: 25576353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
    Lynch TJ; Spigel DR; Brahmer J; Fischbach N; Garst J; Jahanzeb M; Kumar P; Vidaver RM; Wozniak AJ; Fish S; Flick ED; Leon L; Hazard SJ; Kosty MP;
    J Thorac Oncol; 2014 Sep; 9(9):1332-9. PubMed ID: 25122429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
    Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study.
    Leon L; Kosty M; Jahanzeb M; Spigel D; Wozniak AJ; Brahmer J; Fish S; Flick ED; Hazard SJ; Lynch TJ
    Pharmacoepidemiol Drug Saf; 2016 May; 25(5):569-77. PubMed ID: 26748833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study.
    Kosty MP; Wozniak AJ; Jahanzeb M; Leon L; Fish S; Hazard SJ; Lynch TJ
    Target Oncol; 2015 Dec; 10(4):509-16. PubMed ID: 25559289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
    Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
    Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
    J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
    Yamada K; Ichiki M; Takahashi K; Hisamatsu Y; Takeoka H; Azuma K; Shukuya T; Nishikawa K; Tokito T; Ishii H; Hoshino T
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):501-7. PubMed ID: 27402398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.
    Spigel DR; Anthony Greco F; Waterhouse DM; Shipley DL; Zubkus JD; Bury MJ; Webb CD; Hart LL; Gian VG; Infante JR; Burris HA; Hainsworth JD
    Lung Cancer; 2012 Oct; 78(1):70-5. PubMed ID: 22947511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
    Urata Y; Okamoto I; Takeda M; Hattori Y; Okuno K; Shimada T; Kurata T; Kaneda H; Miyazaki M; Terashima M; Tanaka K; Morita S; Nakagawa K; Negoro S; Satouchi M
    Cancer; 2013 Jun; 119(12):2275-81. PubMed ID: 23558513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
    Nishijima-Futami Y; Minami S; Futami S; Koba T; Higashiguchi M; Tamiya M; Suzuki H; Hirashima T; Komuta K; Kijima T
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1215-1220. PubMed ID: 28455584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
    Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
    Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
    Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
    Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab.
    Koyama N
    Cancer Biomark; 2014; 14(4):259-65. PubMed ID: 24934369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Paclitaxel-bevacizumab is a possible alternative as salvage chemotherapy in advanced non-small cell bronchial carcinoma].
    Zarza V; Couraud S; Bosc C; Toffart AC; Moro-Sibilot D; Souquet PJ
    Rev Mal Respir; 2014 Sep; 31(7):601-7. PubMed ID: 25239581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.
    Leon L; Vázquez S; Gracia JM; Casal J; Lazaro M; Firvida JL; Amenedo M; Santome L; Macia S
    Expert Opin Pharmacother; 2012 Jul; 13(10):1389-96. PubMed ID: 22630129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
    Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
    Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.